Better Buy: Fidelity Health Care ETF (FHLC) or iShares Biotechnology ETF (IBB)?
FHLC offers broader sector exposure at a 0.08% expense ratio, compared with IBB's concentrated biotech focus at 0.44%, but IBB delivered stronger 1-year returns despite higher volatility.
Fidelity MSCI Health Care ETF (FHLC) offers broad exposure to the healthcare sector, while iShares Biotechnology ETF (IBB) concentrates its focus on biotechnology companies at a higher cost. Biotechnology is known for acting as a high-beta growth engine within healthcare, but it comes with distinct volatility risks. The iShares Biotechnology ETF specifically tracks this segment, whereas the Fidelity MSCI Health Care ETF casts a wider net across pharmaceutical and healthcare equipment companies.
The comparison between the two ETFs examines how their differing scopes impact long-term risk and return. Beta is a measure of price volatility relative to the S&P 500, calculated from monthly returns over the available fund history, up to five years. The 1-year return represents the total return over the trailing 12 months. Dividend yield refers to the trailing-12-month distribution yield.
To provide a clearer understanding, it is important to note that FHLC offers a more diversified approach to healthcare investing, while IBB provides a more focused strategy on biotechnology stocks, albeit at a higher price point. Investors should consider their risk tolerance and investment objectives when deciding between these two options.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
